Agilent Technologies Inc.
Agilent Technologies, Inc. (A)
Overview
Agilent Technologies, Inc. is a life sciences, diagnostics, and applied chemical-analysis company headquartered in Santa Clara, California. It operates in the health care/life-sciences-tools sector, supplying instruments, software, consumables, and services to analytical laboratories worldwide. Agilent was spun off from Hewlett-Packard in 1999 in what was, at the time, the largest IPO in Silicon Valley history, and later spun off its electronic test-and-measurement business as Keysight Technologies in 2014, leaving Agilent focused purely on life sciences and chemical analysis. For fiscal year 2025 (ended October 31, 2025), Agilent reported revenue of approximately $6.95 billion (up about 6.7% year-over-year) and net income of roughly $1.30 billion, with approximately 18,000 employees worldwide.
What They Do & How They Make Money
Agilent makes and sells the instruments and consumables that scientists, clinical labs, and manufacturers use to analyze chemical and biological samples — for example, gas and liquid chromatography systems, mass spectrometers, spectroscopy instruments, and genomics/PCR-based tools. Revenue comes from a mix of capital equipment sales (the instruments themselves, which labs purchase or lease), high-margin recurring consumables (columns, reagents, vials, and other supplies that must be repurchased regularly to keep instruments running), software for lab data management, and services such as instrument maintenance, calibration, compliance support, and asset-management contracts sold under its "CrossLab" brand. This mix gives Agilent a business model similar to the classic "razor and blades" pattern common in scientific instrumentation: instrument sales open the door to a long tail of recurring consumables and service revenue from the same installed base. Agilent's customers span pharmaceutical and biotech companies (R&D and quality control), clinical and diagnostic laboratories, food and environmental testing labs, chemical and energy companies, academic and government research institutions, and forensics labs — with end markets often described internally as food, environmental and forensics, pharma, diagnostics, chemicals and advanced materials, and research.
Business Segments
Agilent reports revenue across three operating groups:
- Agilent CrossLab Group (~$2.91 billion in FY2025 revenue, the largest segment): Provides consumables (columns, supplies), instrument services, software, and compliance/asset-management support across Agilent's installed base of laboratory instruments, regardless of end market — this is Agilent's recurring-revenue engine.
- Life Sciences & Diagnostics Markets Group (~$2.73 billion in FY2025 revenue): Supplies instruments and consumables — including liquid chromatography, mass spectrometry, spectroscopy, and genomics/PCR-based tools — primarily to pharmaceutical, biotech, clinical diagnostics, and life-sciences research customers.
- Applied Markets Group (~$1.31 billion in FY2025 revenue): Supplies analytical instruments and consumables to non-life-sciences end markets, including chemicals and advanced materials, food safety, environmental and forensics testing, and energy customers.
(Note: Agilent has periodically realigned its segment structure — historically reporting as the Life Sciences and Applied Markets Group, Agilent CrossLab Group, and Diagnostics and Genomics Group — so segment names and groupings can shift modestly from year to year in its filings; the above reflects its most recent reporting structure.)
Competitors
- Broad-line life-sciences tools: Thermo Fisher Scientific is Agilent's largest and most diversified competitor, spanning instruments, consumables, and services across nearly every market Agilent serves. Danaher (through subsidiaries like Beckman Coulter, Pall, and Cepheid) competes across life sciences and diagnostics.
- Chromatography & mass spectrometry: Waters Corporation (liquid chromatography and mass spec, and increasingly biosciences following its pending combination with BD's biosciences and diagnostics solutions business), Bruker (mass spectrometry, NMR, and life-science instruments), and Shimadzu (Japan-based analytical instrumentation) are direct competitors in Agilent's core instrument categories.
- Genomics & diagnostics: Illumina (genomic sequencing), Qiagen, and Bio-Rad Laboratories compete in genomics and molecular diagnostics tools; Roche Diagnostics and Becton Dickinson compete in clinical diagnostics.
- General/applied analytical instruments: PerkinElmer (now Revvity, following its 2023 split) and smaller specialized instrument makers compete in food, environmental, and materials-testing niches.
Competitive Position
Agilent's competitive position rests on a large, entrenched global installed base of analytical instruments and the high-margin, recurring CrossLab consumables and services business that base generates — switching an established lab off Agilent instruments and onto a competitor's platform is costly and disruptive, since methods, software, and staff training are built around specific instrument ecosystems. Agilent also benefits from broad diversification across end markets (pharma, diagnostics, food/environmental, chemicals, and research), which cushions it against a downturn concentrated in any single customer vertical, and from a long-standing reputation for measurement precision and regulatory-compliance support that matters greatly to pharmaceutical and clinical customers operating under strict quality regimes.
Key risks include Agilent's exposure to pharmaceutical and biotech R&D spending cycles, which can slow sharply when biotech funding tightens or when large pharma customers cut capital budgets — a dynamic that has weighed on the broader life-sciences-tools sector at various points in recent years. Agilent also faces a well-capitalized, larger rival in Thermo Fisher Scientific, which can out-invest and out-bundle Agilent across a wider product portfolio, and faces potential consolidation risk among competitors (such as the pending Waters-BD biosciences combination) that could create stronger, more diversified rivals. Additional risks include China exposure (a meaningful revenue market for lab instrumentation that is sensitive to trade policy, tariffs, and local-currency/economic conditions), currency fluctuation given Agilent's global sales footprint, and the capital-intensive, long-cycle nature of instrument sales, which makes revenue somewhat lumpy quarter to quarter. Agilent's strategy has generally centered on shifting its revenue mix toward higher-margin, more predictable CrossLab consumables and services, and on innovation in areas like next-generation mass spectrometry and genomics tools to defend and grow its position against larger and more diversified competitors.